对于Mpox的潜在治疗目标:迄今为止的证据
Siddappa N Byrareddy1, Kalicharan Sharma2, Shrikesh Sachdev3
1Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA.
Expert opinion on therapeutic targets
|June 27, 2023
概括
2022年Mpox疫情突出了对有效治疗的需要. 虽然现有的天花抗病毒药物显示出希望,但Mopox病毒的突变可能会降低它们的疗效,需要MPXV特异性药物开发.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 2022年全球Mpox (MPX) 疫情引发了全世界的公共卫生紧急声明.
- 现有的天花防治措施,包括JYNNEOS疫苗和抗病毒药物Brincidofovir和Tecovirimat,由于Mpox病毒 (MPXV) 和天花病毒之间的遗传相似性,获得了紧急使用授权 (EUA).
研究的目的:
- 审查对Mpox.EU授予的抗病毒药物的历史发展.
- 分析MPXV中的抗病毒耐药性模式.
- 预测MPXV突变对当前抗病毒功能的影响.
主要方法:
- 关于获得 EUA 资助的抗病毒药物的文献评论.
- 分析MPXV和相关的天花病毒中保存的耐药性突变位置.
- 检查2022年MPXV菌株的特征突变.
主要成果:
- 获得 EUA 资助的抗病毒药物对Mpox 显示出良好的疗效.
- 保存的耐药性突变部位和2022年MPXV菌株的特定突变对治疗疗效构成潜在威胁.
- 考虑了艾滋病毒和MPXV共感染个体的治疗结果.
结论:
- 针对MPXV的抗病毒药物对于管理当前和未来的Mpox疫情至关重要.
- 耐药性突变的出现需要开发新的治疗策略.
- 对Mpox病毒学和抗病毒耐药性的持续研究对于公共卫生准备至关重要.
关键词:
布林西多夫维尔 布林西多夫维尔C19L 在线观看这就是Cidofovir.在 F8L 里,蒙波克斯 (Mox Mpox) 是一个OPG57 OPG57 是一个OPG71 OPG71 在线播放德科维里马特的使用方法更多相关视频
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.2K
05:33Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
Published on: September 6, 2024
1.5K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:26Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K